Carnosine vs P21
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Carnosine is an endogenous dipeptide (beta-alanine + histidine) found in high concentrations in muscle and brain. It is a potent anti-aging molecule with broad spectrum antioxidant, anti-glycation, anti-carbonylation, and metal chelating properties, making it one of the most protective naturally occurring dipeptides.
- P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
- Half-Life
- ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
- Not well characterized; likely short, but neurogenic effects persist long after administration
- Admin Route
- Oral, Topical
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 1,000–2,000 mg
- 100–500 mcg
- Frequency
- Once to twice daily with meals
- Once daily
- Key Benefits
- Potent anti-glycation (prevents protein cross-linking/aging)
- Broad-spectrum antioxidant in muscle and brain
- Extends cell lifespan and protects telomeres
- Improves muscle performance and delays fatigue (pH buffering)
- Neuroprotective against Alzheimer's amyloid-beta
- Wound healing acceleration
- Anti-cataract properties (eye health)
- Improves diabetes complications via AGE prevention
- Chelates excess copper and zinc
- Promotes hippocampal neurogenesis
- Enhances spatial memory and learning
- Increases BDNF expression
- Reduces amyloid-beta plaque formation (animal models)
- Anti-tau pathology potential
- Cognitive enhancement without stimulant effects
- Potential therapeutic for Alzheimer's and cognitive aging
- Side Effects
- Very well tolerated
- Rare: mild GI discomfort at high doses
- No significant adverse effects in human studies
- Generally well tolerated in animal studies
- Limited human clinical data
- Injection site reactions
- Potential mild fatigue at initiation
- Stacks With
- —
- —